Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.

Kerr KW, Chang AT, Sulo S, Stutts JT, Panchalingam T, Ryder JR

Childhood obesity (Print)17 Sept 2026

PMID42751742DOI10.1177/21532176261486979PepBankPUB-42751742

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone21

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, 16.88% received a nutritional deficiency or related complication diagnosis within one year.
In plain wordsClaims records showed a nutritional deficiency or related complication diagnosis in 16.88% of pediatric pooled GLP-1RA users within one year.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAny nutritional deficiency or complication
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
16.88%
within 1 year, pooled GLP-1RA users
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174201
02HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, 16.88% received a nutritional deficiency or related complication diagnosis within one year.
In plain wordsClaims records showed a nutritional deficiency or related complication diagnosis in 16.88% of pediatric pooled GLP-1RA users within one year.
Peptide
Liraglutide
Outcome
Not applicableAny nutritional deficiency or complication
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
16.88%
within 1 year, pooled GLP-1RA users
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174202
03HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, 16.88% received a nutritional deficiency or related complication diagnosis within one year.
In plain wordsClaims records showed a nutritional deficiency or related complication diagnosis in 16.88% of pediatric pooled GLP-1RA users within one year.
Peptide
Semaglutide
Outcome
Not applicableAny nutritional deficiency or complication
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
16.88%
within 1 year, pooled GLP-1RA users
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174203
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, vitamin D deficiency was diagnosed in 12.4% within one year.
In plain wordsClaims records showed vitamin D deficiency diagnoses in 12.4% of pediatric pooled GLP-1RA users within one year.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVitamin D deficiency
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
12.4%
vitamin D deficiency
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174204
05HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, vitamin D deficiency was diagnosed in 12.4% within one year.
In plain wordsClaims records showed vitamin D deficiency diagnoses in 12.4% of pediatric pooled GLP-1RA users within one year.
Peptide
Liraglutide
Outcome
Not applicableVitamin D deficiency
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
12.4%
vitamin D deficiency
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174205
06HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, vitamin D deficiency was diagnosed in 12.4% within one year.
In plain wordsClaims records showed vitamin D deficiency diagnoses in 12.4% of pediatric pooled GLP-1RA users within one year.
Peptide
Semaglutide
Outcome
Not applicableVitamin D deficiency
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
12.4%
vitamin D deficiency
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174206
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, nutritional anemia was diagnosed in 1.55% within one year.
In plain wordsClaims records showed nutritional anemia diagnoses in 1.55% of pediatric pooled GLP-1RA users within one year.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNutritional anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.55%
nutritional anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174207
08HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, nutritional anemia was diagnosed in 1.55% within one year.
In plain wordsClaims records showed nutritional anemia diagnoses in 1.55% of pediatric pooled GLP-1RA users within one year.
Peptide
Liraglutide
Outcome
Not applicableNutritional anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.55%
nutritional anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174208
09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, nutritional anemia was diagnosed in 1.55% within one year.
In plain wordsClaims records showed nutritional anemia diagnoses in 1.55% of pediatric pooled GLP-1RA users within one year.
Peptide
Semaglutide
Outcome
Not applicableNutritional anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.55%
nutritional anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174209
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, iron-deficiency anemia was diagnosed in 1.44% within one year.
In plain wordsClaims records showed iron-deficiency anemia diagnoses in 1.44% of pediatric pooled GLP-1RA users within one year.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIron-deficiency anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.44%
iron-deficiency anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174210
11HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, iron-deficiency anemia was diagnosed in 1.44% within one year.
In plain wordsClaims records showed iron-deficiency anemia diagnoses in 1.44% of pediatric pooled GLP-1RA users within one year.
Peptide
Liraglutide
Outcome
Not applicableIron-deficiency anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.44%
iron-deficiency anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174211
12HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA claims, iron-deficiency anemia was diagnosed in 1.44% within one year.
In plain wordsClaims records showed iron-deficiency anemia diagnoses in 1.44% of pediatric pooled GLP-1RA users within one year.
Peptide
Semaglutide
Outcome
Not applicableIron-deficiency anemia
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Nutritional deficiencies · Whole body
Measurements
Diagnosis proportion
1.44%
iron-deficiency anemia
Source sentences
Summary
Within 1 year, 16.88% of patients were diagnosed with at least one nutritional deficiency or deficiency-related complication, most frequently vitamin D deficiency (12.4%), followed by nutritional anemia (1.55%), and iron-deficiency anemia (1.44%).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174212
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In pediatric pooled GLP-1RA claims, 23.3% had a nutrition consultation within 180 days.
In plain wordsClaims records showed nutrition consultations within 180 days in 23.3% of pediatric pooled GLP-1RA users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNutrition consultation utilization
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Nutrition therapy/counseling visit within 180 days
23.3%
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174213
14HumanNot a test of Liraglutide aloneObservational studyOther
In pediatric pooled GLP-1RA claims, 23.3% had a nutrition consultation within 180 days.
In plain wordsClaims records showed nutrition consultations within 180 days in 23.3% of pediatric pooled GLP-1RA users.
Peptide
Liraglutide
Outcome
Not applicableNutrition consultation utilization
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Nutrition therapy/counseling visit within 180 days
23.3%
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174214
15HumanNot a test of Semaglutide aloneObservational studyOther
In pediatric pooled GLP-1RA claims, 23.3% had a nutrition consultation within 180 days.
In plain wordsClaims records showed nutrition consultations within 180 days in 23.3% of pediatric pooled GLP-1RA users.
Peptide
Semaglutide
Outcome
Not applicableNutrition consultation utilization
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Nutrition therapy/counseling visit within 180 days
23.3%
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174215
16HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In pediatric pooled GLP-1RA users, nutrition consultation was linked to more deficiency or complication diagnoses than no consultation.
In plain wordsClaims records linked nutrition consultation to more deficiency or complication diagnoses than no consultation among pediatric pooled GLP-1RA users.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDeficiency diagnoses by consultation
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Comparator
No nutrition consultation
Outcome group
Nutritional deficiencies · Whole body
Measurements
Nutritional deficiency or complication diagnosis rate
23.2%
With nutrition therapy/counseling consultation
Nutritional deficiency or complication diagnosis rate
14.8%
Without nutrition therapy/counseling consultation
Source sentences
Summary
Patients with NT/C consultations had higher rates of nutritional deficiencies and deficiency-related complications than those without (23.2% vs. 14.8%, p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174219
17HumanNot a test of Liraglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA users, nutrition consultation was linked to more deficiency or complication diagnoses than no consultation.
In plain wordsClaims records linked nutrition consultation to more deficiency or complication diagnoses than no consultation among pediatric pooled GLP-1RA users.
Peptide
Liraglutide
Outcome
IncreaseDeficiency diagnoses by consultation
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Comparator
No nutrition consultation
Outcome group
Nutritional deficiencies · Whole body
Measurements
Nutritional deficiency or complication diagnosis rate
23.2%
With nutrition therapy/counseling consultation
Nutritional deficiency or complication diagnosis rate
14.8%
Without nutrition therapy/counseling consultation
Source sentences
Summary
Patients with NT/C consultations had higher rates of nutritional deficiencies and deficiency-related complications than those without (23.2% vs. 14.8%, p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174220
18HumanNot a test of Semaglutide aloneObservational studySafety outcome
In pediatric pooled GLP-1RA users, nutrition consultation was linked to more deficiency or complication diagnoses than no consultation.
In plain wordsClaims records linked nutrition consultation to more deficiency or complication diagnoses than no consultation among pediatric pooled GLP-1RA users.
Peptide
Semaglutide
Outcome
IncreaseDeficiency diagnoses by consultation
Study
Homo sapiensn = 2,031
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Comparator
No nutrition consultation
Outcome group
Nutritional deficiencies · Whole body
Measurements
Nutritional deficiency or complication diagnosis rate
23.2%
With nutrition therapy/counseling consultation
Nutritional deficiency or complication diagnosis rate
14.8%
Without nutrition therapy/counseling consultation
Source sentences
Summary
Patients with NT/C consultations had higher rates of nutritional deficiencies and deficiency-related complications than those without (23.2% vs. 14.8%, p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174221
19HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In pediatric pooled GLP-1RA claims, mean time to first nutrition consultation was 149 days.
In plain wordsClaims records showed a mean of 149 days to first nutrition consultation among pediatric pooled GLP-1RA users.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTime to nutrition consultation
Study
Homo sapiensn: not reported in source
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Mean time to first nutrition therapy/counseling visit
149 days
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275174216
20HumanNot a test of Liraglutide aloneObservational studyOther
In pediatric pooled GLP-1RA claims, mean time to first nutrition consultation was 149 days.
In plain wordsClaims records showed a mean of 149 days to first nutrition consultation among pediatric pooled GLP-1RA users.
Peptide
Liraglutide
Outcome
Not applicableTime to nutrition consultation
Study
Homo sapiensn: not reported in source
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Mean time to first nutrition therapy/counseling visit
149 days
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4275174217
21HumanNot a test of Semaglutide aloneObservational studyOther
In pediatric pooled GLP-1RA claims, mean time to first nutrition consultation was 149 days.
In plain wordsClaims records showed a mean of 149 days to first nutrition consultation among pediatric pooled GLP-1RA users.
Peptide
Semaglutide
Outcome
Not applicableTime to nutrition consultation
Study
Homo sapiensn: not reported in source
Inovalon administrative claims for GLP-1RA users aged 10-17 years, 2017-2022
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Mean time to first nutrition therapy/counseling visit
149 days
pooled pediatric GLP-1RA users
Source sentences
Summary
Only 23.3% had NT/C visit within 180 days (mean time to first visit: 149 days).
3 context sentences(design, population, supporting numbers)
Summary · context
We analyzed Inovalon administrative claims data from 2017 to 2022 covering over 100 million patients to identify 2,031 GLP-1RA users aged 10-17 years who met continuous enrollment criteria and had no prior diagnosis of nutritional deficiency.
Summary · context
Nutritional deficiencies were identified using the International Classification of Diseases, 10th edition codes for up to 1 year following GLP-1RA initiation.
Summary · context
Liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%) were the most prescribed GLP-1RA drugs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4275174218

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.